PMID- 36315280
OWN - NLM
STAT- MEDLINE
DCOM- 20230209
LR  - 20230209
IS  - 1420-908X (Electronic)
IS  - 1023-3830 (Print)
IS  - 1023-3830 (Linking)
VI  - 72
IP  - 1
DP  - 2023 Jan
TI  - Viperin deficiency promotes dendritic cell activation and function via NF-kappaB 
      activation during Mycobacterium tuberculosis infection.
PG  - 27-41
LID - 10.1007/s00011-022-01638-3 [doi]
AB  - OBJECTIVES AND DESIGN: Dendritic cells (DCs) are one of the key immune cells in 
      bridging innate and adaptive immune response against Mycobacterium tuberculosis 
      (Mtb) infection. Interferons (IFNs) play important roles in regulating DC 
      activation and function. Virus-inhibitory protein, endoplasmic 
      reticulum-associated, interferon-inducible (Viperin) is one of the important 
      IFN-stimulated genes (ISGs), and elicits host defense against infection. METHODS: 
      We investigated the effects and mechanisms of Viperin on DC activation and 
      function using Viperin deficient bone marrow-derived dendritic cells (BMDCs) 
      during Mtb infection. RESULTS: Viperin deficiency enhanced phagocytic activity 
      and increased clearance of Mtb in DCs, produced higher abundance of NO, cytokine 
      including interleukin-12 (IL-12), Tumor necrosis factor-alpha (TNF-alpha), IL-1beta, IL-6 
      and chemokine including CXCL1, CXCL2 and CXCL10, elevated MHC I, MHC II and 
      co-stimulatory molecules expression, and enhanced CD4(+) and CD8(+) T cell 
      responses. Mechanistically, Viperin deficiency promoted DC activation and 
      function through NF-kappaB p65 activation. NF-kappaB p65 inhibitor prevented cytokine and 
      chemokine production, and co-stimulatory molecules expression promoted by Viperin 
      deficiency. CONCLUSIONS: These results suggest that Mtb induced Viperin 
      expression could impair the activation of host defense function of DCs and DC-T 
      cell cross talk during Mtb infection. This research may provide a potential 
      target for future HDT in TB therapy.
CI  - (c) 2022. The Author(s).
FAU - Zhou, Xinying
AU  - Zhou X
AD  - Institute of Molecular Immunology, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University, Guangzhou, 510515, China. 
      zxyforever@smu.edu.cn.
FAU - Xu, Hui
AU  - Xu H
AD  - Institute of Molecular Immunology, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University, Guangzhou, 510515, China.
FAU - Li, Qianna
AU  - Li Q
AD  - Institute of Molecular Immunology, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University, Guangzhou, 510515, China.
FAU - Wang, Qi
AU  - Wang Q
AD  - Institute of Molecular Immunology, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University, Guangzhou, 510515, China.
FAU - Liu, Honglin
AU  - Liu H
AD  - Institute of Molecular Immunology, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University, Guangzhou, 510515, China.
FAU - Huang, Yingqi
AU  - Huang Y
AD  - Institute of Molecular Immunology, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University, Guangzhou, 510515, China.
FAU - Liang, Yao
AU  - Liang Y
AD  - Institute of Molecular Immunology, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University, Guangzhou, 510515, China.
FAU - Lie, Linmiao
AU  - Lie L
AD  - Institute of Molecular Immunology, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University, Guangzhou, 510515, China.
FAU - Han, Zhenyu
AU  - Han Z
AD  - Institute of Molecular Immunology, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University, Guangzhou, 510515, China.
FAU - Chen, Yaoxin
AU  - Chen Y
AD  - Institute of Molecular Immunology, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University, Guangzhou, 510515, China.
FAU - Huang, Yulan
AU  - Huang Y
AD  - Institute of Molecular Immunology, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University, Guangzhou, 510515, China.
FAU - Zhou, Wenle
AU  - Zhou W
AD  - Institute of Molecular Immunology, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University, Guangzhou, 510515, China.
FAU - Wen, Qian
AU  - Wen Q
AD  - Institute of Molecular Immunology, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University, Guangzhou, 510515, China.
FAU - Zhou, Chaoying
AU  - Zhou C
AD  - Institute of Molecular Immunology, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University, Guangzhou, 510515, China.
FAU - Hu, Shengfeng
AU  - Hu S
AD  - Institute of Molecular Immunology, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University, Guangzhou, 510515, China.
FAU - Ma, Li
AU  - Ma L
AD  - Institute of Molecular Immunology, School of Laboratory Medicine and 
      Biotechnology, Southern Medical University, Guangzhou, 510515, China. 
      mali_61648322@smu.edu.cn.
LA  - eng
GR  - 82070010/National Natural Science Foundation of China/
GR  - 82072242/National Natural Science Foundation of China/
GR  - 2019A1515010988/Guangdong Basic and Applied Basic Research Foundation/
GR  - 2021A1515010933/Guangdong Basic and Applied Basic Research Foundation/
PT  - Journal Article
DEP - 20221031
PL  - Switzerland
TA  - Inflamm Res
JT  - Inflammation research : official journal of the European Histamine Research 
      Society ... [et al.]
JID - 9508160
RN  - 0 (Chemokines)
RN  - 0 (Cytokines)
RN  - 0 (NF-kappa B)
RN  - 0 (Viperin Protein)
SB  - IM
MH  - Chemokines/metabolism
MH  - Cytokines
MH  - Dendritic Cells
MH  - *Mycobacterium tuberculosis/metabolism
MH  - NF-kappa B/metabolism
MH  - *Tuberculosis
MH  - *Viperin Protein/metabolism
MH  - Animals
PMC - PMC9902321
OTO - NOTNLM
OT  - Dendritic cells (DCs)
OT  - Immune responses
OT  - Mycobacterium tuberculosis (Mtb)
OT  - NF-kappaB
OT  - Viperin
COIS- The authors declare no competing interests. The authors declare that the research 
      was conducted in the absence of any commercial or financial relationships that 
      could be construed as a potential conflict of interest.
EDAT- 2022/11/01 06:00
MHDA- 2023/02/09 06:00
PMCR- 2022/10/31
CRDT- 2022/10/31 12:14
PHST- 2022/05/16 00:00 [received]
PHST- 2022/09/01 00:00 [accepted]
PHST- 2022/08/30 00:00 [revised]
PHST- 2022/11/01 06:00 [pubmed]
PHST- 2023/02/09 06:00 [medline]
PHST- 2022/10/31 12:14 [entrez]
PHST- 2022/10/31 00:00 [pmc-release]
AID - 10.1007/s00011-022-01638-3 [pii]
AID - 1638 [pii]
AID - 10.1007/s00011-022-01638-3 [doi]
PST - ppublish
SO  - Inflamm Res. 2023 Jan;72(1):27-41. doi: 10.1007/s00011-022-01638-3. Epub 2022 Oct 
      31.